NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) stock
NMTCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 11/3079% below fair value
$0.71−0.04 (-5.15%)
Close on Nov 17, 2026Market cap $6.43MP/E –Yield –
Neuroone Medical Technologies r&d expenses
Research and development expenses are spending on new products and technology.
Neuroone Medical Technologies's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.40M, up 8.5% year over year. For fiscal 2025 it was $4.98M, down 1.6% from the year before. The highest annual figure on record is $6.94M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.98M | -1.6% |
| FY2024 | Sep 30, 2024 | $5.07M | -27.0% |
| FY2023 | Sep 30, 2023 | $6.94M | +40.8% |
| FY2022 | Sep 30, 2022 | $4.93M | +25.6% |
| FY2021 | Sep 30, 2021 | $3.93M | +89.1% |
| FY2020 | Sep 30, 2020 | $2.08M | +182.3% |
| FY2017 | Dec 31, 2017 | $735.33K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $1.43M | +20.5% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $1.47M | -2.8% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $1.39M | +18.6% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $1.12M | +0.4% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $1.18M | -1.0% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $1.51M | +18.6% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $1.17M | -21.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $1.11M | -37.4% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $1.19M | -36.8% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $1.27M | -25.4% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $1.48M | -5.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $1.78M | +23.7% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $1.89M | +54.4% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $1.71M | +41.6% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $1.56M | +47.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $1.44M | +42.6% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $1.23M | +36.0% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $1.21M | +11.5% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $1.06M | +13.5% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $1.01M | +28.5% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $901.13K | +101.5% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $1.08M | +216.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $934.16K | +86.2% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $784.72K | +234.0% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $447.15K | +64.6% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $342.10K | +118.3% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $501.82K | +596.6% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $234.93K | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $271.65K | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $156.72K | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $72.04K | – |
See a number that looks wrong?